Skip to main content
Jonathan Corcoran

Professor Jonathan Corcoran PhD

Professor of Neuroscience

Research interests

  • Neuroscience

Biography

We are interested in discovering drugs for treatment of central nervous system (CNS) disorders, including Alzheimer’s disease (AD), motoneuron disease (MND), traumatic brain injury (TBI), spinal cord injury (SCI) and neuropathic pain (NP). Retinoic acid (RA) signalling is important for the maintenance and regeneration of the CNS. The receptors involved in this are retinoic acid receptors (RARs) of which there are three types: alpha, beta and gamma. Our translational programs have run from bench to clinic. Work funded by the Wellcome Trust and MRC has allowed for us develop a first in class orally available RAR beta drug (KCL 286) to treat CNS disorders, where axonal outgrowth, new nerve connections and reduction of inflammation are required. This includes SCI, for which there are no treatments. We already have a multicentre phase IIA trial set up and funding is being sought from various streams.

Please see my Research Staff Profile for more detail.

News

New orally available drug for spinal cord injury found to be safe and tolerable in healthy participants

New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London has demonstrated the safety and tolerability of a...

Drugs

News

New orally available drug for spinal cord injury found to be safe and tolerable in healthy participants

New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London has demonstrated the safety and tolerability of a...

Drugs